ABEO - Abeona Therapeutics Inc. Stock Price and Quote

ABEO | Abeona Therapeutics Inc. | [NASD]

Index	-	P/E	-	EPS (ttm)	-4.18	Insider Own	3.30%	Shs Outstand	16.90M	Perf Week	1.29%
Market Cap	60.29M	Forward P/E	-	EPS next Y	-2.18	Insider Trans	0.59%	Shs Float	16.25M	Perf Month	0.32%
Income	-31.80M	PEG	-	EPS next Q	-0.74	Inst Own	7.10%	Short Float / Ratio	2.26% / 2.57	Perf Quarter	37.12%
Sales	1.10M	P/S	54.81	EPS this Y	74.40%	Inst Trans	35.89%	Short Interest	0.37M	Perf Half Y	-20.30%
Book/sh	1.11	P/B	2.83	EPS next Y	12.80%	ROA	-63.30%	Target Price	22.67	Perf Year	-18.07%
Cash/sh	2.10	P/C	1.49	EPS next 5Y	-	ROE	-157.00%	52W Range	2.19 - 6.13	Perf YTD	1.95%
Dividend	-	P/FCF	-	EPS past 5Y	19.50%	ROI	-190.00%	52W High	-48.78%	Beta	1.26
Dividend %	-	Quick Ratio	5.80	Sales past 5Y	11.10%	Gross Margin	-	52W Low	43.38%	ATR	0.20
Employees	57	Current Ratio	5.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	52.34	Volatility	7.67% 6.68%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	85.80%	Profit Margin	-	Rel Volume	0.69	Prev Close	3.21
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 24 BMO	Payout	-	Avg Volume	142.43K	Price	3.14
Recom	2.00	SMA20	0.21%	SMA50	6.30%	SMA200	-4.37%	Volume	98,473	Change	-2.18%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-11-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$4
Sep-18-20	Initiated	B. Riley FBR	Buy	$5
Feb-10-20	Initiated	SVB Leerink	Outperform	$6
Dec-10-19	Resumed	Cantor Fitzgerald	Neutral	$2 → $4
Aug-15-19	Downgrade	Maxim Group	Buy → Hold
Aug-12-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$29 → $2
Jul-26-19	Downgrade	Mizuho	Buy → Neutral	$17 → $4
Jun-27-19	Initiated	Mizuho	Buy
Oct-12-18	Initiated	Mizuho	Buy	$17
Jun-05-18	Initiated	Seaport Global Securities	Buy	$29
Nov-08-17	Initiated	SunTrust	Buy	$26
Oct-16-17	Reiterated	H.C. Wainwright	Buy	$20 → $30
Oct-11-17	Reiterated	Cantor Fitzgerald	Overweight	$21 → $34
Oct-10-17	Initiated	Citigroup	Buy	$32
Oct-05-17	Reiterated	Maxim Group	Buy	$17 → $35
Sep-15-17	Initiated	RBC Capital Mkts	Outperform	$23
Jul-18-17	Reiterated	Maxim Group	Buy	$14 → $17
Jun-22-17	Resumed	Jefferies	Buy	$22
Jan-06-17	Initiated	Jefferies	Buy
Sep-29-16	Reiterated	Maxim Group	Buy	$8 → $14

Show Previous Ratings

May-25-23 12:27AM	Q1 2023 Abeona Therapeutics Inc Earnings Call and Portfolio Update Conference Call (Thomson Reuters StreetEvents)
May-22-23 07:30AM	Abeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio Update Conference Call to May 24, 2023 (GlobeNewswire)
May-16-23 09:00AM	Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (GlobeNewswire)
May-13-23 08:15AM	Abeona Therapeutics First Quarter 2023 Earnings: US$0.54 loss per share (vs US$3.59 loss in 1Q 2022) (Simply Wall St.)
May-11-23 07:30AM	Abeona Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire) -7.19%
07:00AM	Loading…
07:00AM	Abeona Therapeutics Announces Additional Phase 3 VIITAL Study Results for EB-101 Presented at the International Societies for Investigative Dermatology 2023 Meeting (GlobeNewswire)
Apr-18-23 07:15AM	ABEO: Initiating Coverage of Abeona Therapeutics Inc.; Using Gene Therapy to Treat Orphan Diseases (Zacks Small Cap Research)
Apr-10-23 07:30AM	Abeona Therapeutics Announces Multiple Abstracts Accepted from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (GlobeNewswire)
Mar-31-23 06:22AM	Companies Like Abeona Therapeutics (NASDAQ:ABEO) Could Be Quite Risky (Simply Wall St.)
Mar-29-23 07:30AM	Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-24-23 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants (GlobeNewswire) +11.52%
Mar-16-23 07:30AM	Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting (GlobeNewswire)
Mar-14-23 07:30AM	Abeona Therapeutics Announces Update on AAV Ophthalmology Program (GlobeNewswire)
Nov-14-22 07:30AM	Abeona Therapeutics Reports Third Quarter 2022 Financial Results (GlobeNewswire) -5.47%
Nov-08-22 02:28PM	Cantor Bullish On Abeona Saying Recent Trial Data 'Best Case Scenario' (Benzinga)
12:44PM	Loading…
Nov-03-22 12:44PM	Abeona Therapeutics Touts Positive Data From Pivotal EB-101 Study In Blistering Skin Disorder (Benzinga) -13.23%
07:31AM	Abeona Therapeutics Announces $35 Million Private Placement Financing (GlobeNewswire)
07:30AM	Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL Study of EB-101 (GlobeNewswire)
Oct-19-22 07:30AM	Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) (GlobeNewswire) -8.09%
Oct-04-22 07:30AM	Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) (GlobeNewswire)
Sep-22-22 07:30AM	Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit (GlobeNewswire) -9.22%
Sep-13-22 07:30AM	Abeona Therapeutics to Participate in the Cantor Fitzgerald Cell and Genetic Medicines Conference (GlobeNewswire)
Sep-08-22 08:48AM	10 Best Penny Stocks to Buy in September (Insider Monkey)
Aug-11-22 07:30AM	Abeona Therapeutics Reports Second Quarter 2022 Financial Results (GlobeNewswire) +12.02%
Jul-20-22 07:30AM	Abeona Therapeutics Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Jun-24-22 10:08AM	F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm (Zacks) -8.94%
Jun-13-22 01:27PM	FDA Committee Endorses bluebird's (BLUE) Thalassemia Therapy (Zacks) -6.18%
Jun-10-22 03:30PM	FDA Committee Recommends bluebird's (BLUE) CALD Therapy (Zacks)
Jun-08-22 01:21PM	bluebird (BLUE) Up as FDA Nod Likely for Thalassemia Therapy (Zacks) +8.49%
Jun-06-22 02:04PM	AstraZeneca (AZN) Breast Cancer Drug Cuts Risk of Death to Half (Zacks)
07:30AM	Loading…
07:30AM	Abeona Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
Jun-01-22 02:25PM	BioMarin (BMRN) Delays FDA Re-Submission for Hemophilia Drug (Zacks) -7.84%
May-31-22 02:27PM	Amicus' (FOLD) Galafold Aids Growth, Overdependence a Woe (Zacks)
May-25-22 02:29PM	Aerie (AERI) Starts Late-Stage Study to Treat Dry Eye Disease (Zacks)
May-23-22 03:32PM	Athersys (ATHX) Down as Ischemic Stroke Study Fails to Meet Goal (Zacks)
May-19-22 03:02PM	Enanta's (ENTA) RSV Drug Fails to Meet Study Goal, Stock Drops (Zacks)
07:30AM	Abeona Therapeutics Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule (GlobeNewswire)
May-18-22 03:12PM	AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study (Zacks) -7.03%
11:47AM	Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate (Zacks)
May-17-22 09:27AM	AbbVie (ABBV) Buys Option Rights to NextGen Inflammation Drug (Zacks)
08:00AM	Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics (GlobeNewswire)
May-13-22 07:30AM	Abeona Therapeutics Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-12-22 02:47PM	AbbVie's (ABBV) Rinvoq Meets Crohn's Disease Study Goals (Zacks) +15.09%
May-11-22 02:28PM	Epizyme (EPZM) Q1 Earnings Miss, Revenues Lag Estimates (Zacks) -14.69%
May-10-22 02:36PM	Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Top Estimates (Zacks)
11:37AM	Bausch (BHC) Q1 Earnings and Revenues Miss, Stock Down (Zacks)
May-06-22 03:48PM	Aerie (AERI) Q1 Loss Wider Than Expected, Revenues Rise Y/Y (Zacks) -9.37%
03:38PM	ChemoCentryx (CCXI) Q1 Earnings and Sales Miss Estimates (Zacks)
May-04-22 07:30AM	Abeona Therapeutics Announces AAV204, a Novel AAV Capsid, Demonstrated Robust Macular Transduction Following Para-Retinal Administration in Non-Human Primates (GlobeNewswire)
May-03-22 07:00AM	Dianthus, a new $100M startup, aims to make autoimmune treatments easier (American City Business Journals)
Apr-29-22 09:00AM	Abeona Therapeutics Announces Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting (GlobeNewswire) -7.07%
07:30AM	Abeona Therapeutics Announces Pricing of $25 Million Private Placement of Convertible Redeemable Preferred Stock (GlobeNewswire)
Apr-19-22 10:51AM	Can Abeona Therapeutics (NASDAQ:ABEO) Afford To Invest In Growth? (Simply Wall St.)
Mar-31-22 07:30AM	Abeona Therapeutics Announces Strategy Update and 2021 Financial Results (GlobeNewswire)
Mar-28-22 11:20AM	Abeona Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit (GlobeNewswire)
Mar-14-22 07:30AM	Abeona Therapeutics Achieves Target Enrollment in Pivotal Phase 3 VIITAL Study of EB-101 in RDEB (GlobeNewswire)
Jan-25-22 10:00AM	Here's Why Abeona Therapeutics (ABEO) Looks Ripe for Bottom Fishing (Zacks) +7.57%
Dec-22-21 07:30AM	Abeona Therapeutics Issues Letter to Shareholders (GlobeNewswire)
Dec-17-21 09:00AM	Abeona Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants (GlobeNewswire) -39.97%
Dec-16-21 04:01PM	Abeona Therapeutics Announces Public Offering of Common Stock and Warrants (GlobeNewswire) -6.39%
Dec-02-21 07:25AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
Nov-19-21 10:00AM	Down 15.2% in 4 Weeks, Here's Why Abeona Therapeutics (ABEO) Looks Ripe for a Turnaround (Zacks)
Nov-18-21 07:30AM	Abeona Therapeutics Announces Support of EB Research Partnership's Venture Into Cures Event to Raise Awareness for Education and Research of Epidermolysis Bullosa (GlobeNewswire) -9.76%
Nov-17-21 07:30AM	Abeona Therapeutics Announces Presentation on Pivotal Transpher A Study of ABO-102 in MPS IIIA at the 14th ICIEM Conference (GlobeNewswire)
Nov-16-21 07:30AM	Abeona Therapeutics Announces Participation at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-15-21 07:45AM	Abeona Therapeutics Reports Third Quarter Financial Results (GlobeNewswire)
07:12AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Oct-21-21 07:30AM	Abeona Therapeutics to Present at Jefferies Gene Therapy/Editing Summit (GlobeNewswire)
06:21AM	Abeona Therapeutics (NASDAQ:ABEO) investors are sitting on a loss of 90% if they invested three years ago (Simply Wall St.)
Oct-13-21 07:30AM	Abeona Therapeutics Announces Clinical Data Presentations at Upcoming Scientific Congresses (GlobeNewswire)
Oct-12-21 07:30AM	Abeona Therapeutics Appoints Gene Therapy Quality Leader Jon Voss as Vice President, Head of Quality (GlobeNewswire)
Sep-21-21 04:01PM	Abeona Announces New Chairman, Executive Leadership Promotions and Key Talent Additions for Final Push Towards Two Biologics License Application (BLA) Filings (GlobeNewswire)
Sep-07-21 07:30AM	Abeona Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-10-21 07:30AM	Abeona Therapeutics Appoints Edward Carr as Chief Financial Officer (GlobeNewswire)
Jul-28-21 04:01PM	Abeona Therapeutics Reports Second Quarter Financial Results (GlobeNewswire)
07:30AM	Abeona Therapeutics Announces Successful Type B Meeting with U.S. FDA for ABO-102 AAV-based Gene Therapy in Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
Jul-26-21 07:30AM	Abeona Therapeutics Announces New MRI Data Showing Increased Brain Volume in Young Patients with Sanfilippo Syndrome Type A (MPS IIIA) After Treatment with ABO-102 Gene Therapy (GlobeNewswire)
06:12AM	Abeona Reports Positive Data for Sanfilippo Syndrome Treatment (TheStreet.com)
Jul-23-21 07:30AM	Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL Study for Recessive Dystrophic Epidermolysis Bullosa (GlobeNewswire)
Jul-07-21 12:02PM	Abeona Unveils Additional Data From Gene Therapy Trial For Rare Connective Tissue Disorder (Benzinga)
07:30AM	Abeona Therapeutics Announces Updated EB-101 Phase 1/2a Clinical Results in Recessive Dystrophic Epidermolysis Bullosa at the Society for Pediatric Dermatology 46th Annual Meeting (GlobeNewswire)
Jun-14-21 10:00AM	10 Penny Stocks Robinhood Traders are Buying in 2021 (Insider Monkey)
Jun-02-21 07:30AM	Abeona Therapeutics to Present at Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-26-21 07:30AM	Abeona Therapeutics Issues Letter to Stockholders (GlobeNewswire) +10.74%
May-25-21 07:30AM	Abeona Therapeutics Appoints Head of Research & Clinical Development (GlobeNewswire)
06:45AM	Abeona Therapeutics, Inc. to Host Earnings Call (ACCESSWIRE)
May-18-21 07:30AM	Abeona Therapeutics Reports First Quarter Financial Results (GlobeNewswire) +14.71%
May-11-21 06:06AM	Moving Average Crossover Alert: Abeona Therapeutics (ABEO) (Zacks)
Apr-20-21 07:30AM	Abeona Therapeutics Announces Presentation on New Preclinical Data Supporting the Potential of Cre-Mediated Dual AAV Vector Technology to Enable Delivery of Large Genes Targeted for Treatment of Stargardt Disease at ARVO 2021 Annual Meeting (GlobeNewswire)
Apr-19-21 07:30AM	Abeona Therapeutics Appoints Two Industry Leaders as New Independent Members to Its Board of Directors (GlobeNewswire) -5.37%
Mar-25-21 07:30AM	Abeona Therapeutics Announces Appointment of Two New Independent Members to its Board of Directors (GlobeNewswire) +5.62%
Mar-24-21 05:15PM	Abeona Therapeutics (ABEO) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -6.32%
04:01PM	Abeona Therapeutics Announces 2020 Financial Results and Recent Operational Progress (GlobeNewswire)
Mar-23-21 12:41PM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Abeona Therapeutics Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors (PR Newswire) -6.86%
Mar-22-21 07:30AM	Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Executive Officer (GlobeNewswire) -6.42%
Mar-11-21 11:22PM	Abeona Therapeutics' (NASDAQ:ABEO) Shareholders Are Down 85% On Their Shares (Simply Wall St.)
Feb-25-21 11:33AM	Billionaire Ken Griffin Pulls the Trigger on These 2 Penny Stocks (TipRanks) +13.18%
Feb-22-21 07:30AM	Abeona Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire) -7.47%
Feb-12-21 11:36AM	New Positive Phase 1/2 Interim Data Presented at WORLDSymposium Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeonas ABO-102 Gene Therapy (GlobeNewswire) -11.90%
Feb-02-21 07:30AM	Abeona Therapeutics Announces Clinical Investigator Webinar to Review ABO-102 and ABO-101 Clinical Data Presented at the 17th Annual WORLDSymposium (GlobeNewswire)

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Alvino Mark	Director	Apr 25	Sale	3.25	887	2,883	17,527	May 05 04:05 PM
Amoroso Michael	Director	Mar 20	Sale	2.33	268	624	56,441	Mar 21 05:13 PM
Amoroso Michael	Director	Mar 03	Sale	2.38	1,002	2,385	56,709	Mar 03 07:06 PM
O'Malley Brendan M.	SVP, General Counsel	Dec 09	Buy	3.13	5,869	18,370	93,830	Dec 12 04:10 PM
O'Malley Brendan M.	SVP, General Counsel	Nov 18	Buy	3.99	7,500	29,925	87,961	Nov 21 09:00 AM
Vazzano Joseph Walter	Chief Financial Officer	Nov 18	Buy	4.00	2,500	10,000	95,250	Nov 21 09:00 AM
Alvino Mark	Director	Jun 15	Sale	0.15	20,000	3,098	27,181	Jun 17 04:17 PM
Alvino Mark	Director	Jun 06	Sale	0.16	35,000	5,464	47,181	Jun 07 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience